Selegiline metabolism defect · Cognitive enhancer drug sensitivity · Altered metabolism of cognitive enhancers · Metabolizer of a cognitive enhancer · CYP1A2 mutation · CYP1A2 deficiency · CYP1A2-Mangel · Poor metabolizer of AC-3933
This genetic condition involves a mutation in the CYP1A2 gene, which affects how the liver processes certain medications, specifically cognitive enhancers like selegiline. Because of this liver enzyme deficiency, affected dogs metabolize these specific drugs much slower than normal. This slower breakdown can lead to a buildup of the medication in the bloodstream, altering its effects.
The genetic variant itself does not cause any visible symptoms or health limitations in daily life. Owners would only notice issues, such as signs of drug sensitivity or overdose, if the dog is prescribed specific cognitive medications in its senior years.
No treatment is needed for the genetic variant itself, but veterinarians must adjust drug dosages or select alternative medications if cognitive therapy is required. Managing this condition is straightforward and carries a typical cost of 0 to 100 EUR for alternative prescriptions.
Estimated range of typical treatment cost. Actual cost depends on severity, clinic and region.
More conditions affecting the General / metabolic.